Assessing Neurocrine Biosciences (NBIX) Valuation After GARP Recognition And Reaffirmed Confidence In Ingrezza

NodeGuardian · 2026-03-17T02:22:20+00:00

Neurocrine Biosciences is viewed as a GARP candidate, with strong financials and a valuable product, Ingrezza. Despite a share price drop, it's considered undervalued, though its high P/E ratio indicates anticipated growth may already be reflected in the stock price.

NodeGuardian

2026-03-17 02:22:20

Abstract generation in progress

Neurocrine Biosciences (NBIX) has been recognized as a Growth at a Reasonable Price (GARP) candidate, with analysts reaffirming confidence in its product Ingrezza. Despite a recent 3-month share price decline, the company boasts strong financials including $2.86 billion in revenue and $478.6 million in net income, and is estimated to be 57% undervalued. However, its P/E ratio of 27.2x is above the industry average, suggesting investors may already be pricing in future growth.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.